These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 9926144)
1. Salmeterol xinafoate: an analysis of outcomes and cost-effectiveness using a primary care database. Price DB; Cargill K; Wolfe S; Darby H Respir Med; 1998 Nov; 92(11):1302-4. PubMed ID: 9926144 [No Abstract] [Full Text] [Related]
5. Why SMART about second-line treatment when first-line treatment is being ignored? Currie GP Chest; 2006 Sep; 130(3):929; author reply 929. PubMed ID: 16963701 [No Abstract] [Full Text] [Related]
6. Safety of long-acting beta-agonists--an urgent need to clear the air. Martinez FD N Engl J Med; 2005 Dec; 353(25):2637-9. PubMed ID: 16371628 [No Abstract] [Full Text] [Related]
7. Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K. Price DB; Ben-Joseph RH; Zhang Q Respir Med; 2001 Jan; 95(1):83-9. PubMed ID: 11207023 [TBL] [Abstract][Full Text] [Related]
9. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol. Frois C; Wu EQ; Ray S; Colice GL Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019 [TBL] [Abstract][Full Text] [Related]
10. Cost comparison of beta 2-agonist bronchodilators used in the treatment of asthma. Nightingale CH Pharmacotherapy; 1995; 15(5):677-81. PubMed ID: 8570443 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma. Rutten-van Mölken MP; van Doorslaer EK; Till MD Pharmacoeconomics; 1998 Dec; 14(6):671-84. PubMed ID: 10346418 [TBL] [Abstract][Full Text] [Related]
13. Drug safety and salmeterol: the controversy continues. Weiss KB Ann Intern Med; 2008 Jul; 149(1):56-7. PubMed ID: 18523131 [No Abstract] [Full Text] [Related]
14. The clinical trials in the initial five-year award period of the Asthma Clinical Research Network. Chinchilli VM; Drazen JM; Fish JE; Lemanske RF; Lazarus SC; Martin RJ; Control Clin Trials; 2001 Dec; 22(6 Suppl):126S-34S. PubMed ID: 11728619 [TBL] [Abstract][Full Text] [Related]
15. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Bateman E; Nelson H; Bousquet J; Kral K; Sutton L; Ortega H; Yancey S Ann Intern Med; 2008 Jul; 149(1):33-42. PubMed ID: 18523132 [TBL] [Abstract][Full Text] [Related]
16. Salmeterol xinafoate in asthma. Palmer JB; Oxford JM JAMA; 1994 Nov 23-30; 272(20):1575-6. PubMed ID: 7966861 [No Abstract] [Full Text] [Related]
17. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. Stempel DA; O'Donnell JC; Meyer JW J Allergy Clin Immunol; 2002 Mar; 109(3):433-9. PubMed ID: 11897987 [TBL] [Abstract][Full Text] [Related]
18. Inhaled salmeterol and albuterol in asthmatic patients receiving high-dose inhaled corticosteroids. Lai CK; Chan CH; Ho SS; Hui AC; Lai KN Chest; 1995 Jul; 108(1):36-40. PubMed ID: 7606988 [TBL] [Abstract][Full Text] [Related]
19. Tiotropium in combination with placebo, salmeterol, or fluticasone salmeterol for chronic obstructive pulmonary disease: possible confounding effect of treatment withdrawal? Brown SM Ann Intern Med; 2007 Dec; 147(12):882; author reply 882-3. PubMed ID: 18087061 [No Abstract] [Full Text] [Related]
20. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]